口服使用金属烯酸启发的黄自组装剂,以缓解大肠炎
Xiaojuan Chen1,2,3, Weiyi Sun1,2, Bin Zhou4
1College of Food Science and Technology, Huazhong Agricultural University, Wuhan 430070, China.
Journal of agricultural and food chemistry
|January 6, 2026
概括
这项研究开发了结合黄素,酸和的新型纳米颗粒,用于治疗性结肠炎 (UC). 这些纳米粒子增强了生物可用性和治疗效果,用于控制肠道炎症.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 天然生物活性化合物显示出性结肠炎 (UC) 治疗的潜力,但其生物可用性和有效性较低.
- 开发有效的药物输送系统对于改善UC管理中的治疗结果至关重要.
研究的目的:
- 开发一种口服,生物相容的纳米粒子系统 (CTAl NPs),使用自组装策略来增强UC处理.
- 在纳米粒子系统中研究素,酸和 (Al3+) 的协同治疗机制.
主要方法:
- 通过自组装制造CTAlNP,将黄素 (Cur) 封装在酸 (TA) 和Al3+协调网络中.
- 纳米粒子相互作用的表征,包括结,π-π堆叠和协调相互作用.
- 对CTAlNP在通过抗炎,抗氧化,免疫调节和肠道屏障强化来管理UC的治疗疗效的评估.
主要成果:
- 在TA-Al3+协调网络中成功封装黄素,形成稳定的CTALNP.
- CTAl NPs显示出协同作用的治疗效果,包括强大的抗炎和抗氧化活性.
- 这些纳米颗粒有效地恢复了免疫平衡,并加强了肠道屏障,改善了UC管理.
结论:
- 开发的CTALNP为治疗性结肠炎提供了一种简单,安全和高效的方法.
- 这种跨学科的策略为使用基于纳米技术的生物活性化合物治疗与炎症有关的疾病提供了更广泛的见解.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
449
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
449
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480
01:21Drugs for Treatment of Constipation-Predominant IBS
698
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
698
01:29Inflammatory Bowel Disease IV: Pharmacological Management
471
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
471
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
631
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
631